NT: As a cyclone bears down on Australia, memories turn to Darwin 1974. exit RELATED:Tourist dies in crash: Debbie ‘to be worse than Yasi’ It was a miracle fewer than 100 people died from a population of nearly 40,000 when Cyclone Tracy barreled into Darwin on Christmas eve in 1974. As Cyclone Debbie today bears down […]

by

The Weed Blog is excited to announce that one of Oregon’s premier cannabis farms, Yerba Buena, has created and released their highest testing CBD strain, “Corazon” (Spanish for “Heart”). This new highest testing CBD strain is a cross between Charlotte’s Web and AC/DC. Testing at 22.5% CBD and 2.71% THC by Pixis Labs under Oregon’s ORELAP-certified […]

by

Maxim Group started coverage on shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) in a report released on Thursday. The brokerage issued a buy rating and a $135.00 price objective on the biopharmaceutical company’s stock. “Epilepsy remains a challenging indication to treat, with over a third of patients (750k patients in the U.S.) who are inadequately controlled […]

by

LONDON, March 29, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to GW’s investigational product Epidiolex® (cannabidiol or CBD) […]

by

VANCOUVER, British Columbia, April 25, 2017 (GLOBE NEWSWIRE) — Kalytera Therapeutics, Inc. (KALY.V), a clinical-stage biopharmaceutical company developing next-generation cannabinoid-derived therapeutics, today announced that it has developed the multi-center location component of the plan for the proposed clinical trials to evaluate cannabidiol (“CBD”) for the prevention and treatment of Graft versus Host Disease (“GvHD”). Kalytera […]

by

VANCOUVER, British Columbia, April 25, 2017 (GLOBE NEWSWIRE) — Kalytera Therapeutics, Inc. (TSXV:KALY), a clinical-stage biopharmaceutical company developing next-generation cannabinoid-derived therapeutics, today announced that it has developed the multi-center location component of the plan for the proposed clinical trials to evaluate cannabidiol (“CBD”) for the prevention and treatment of Graft versus Host Disease (“GvHD”). Kalytera […]

by

Equities researchers at Maxim Group initiated coverage on shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) in a research note issued to investors on Thursday. The brokerage set a “buy” rating and a $135.00 price target on the biopharmaceutical company’s stock. Maxim Group’s price target suggests a potential upside of 17.64% from the stock’s current price. The […]

by

Many parents come to my office seeking help for their children suffering with autism.   The three main symptoms that are challenging for these families are communication difficulties, repetitive behaviors, and social challenges, including tantrums and self-injurious behavior.  Although the FDA has approved two medications, both antipsychotics, for treating the irritability associated with autism, they have […]

by

In the Phase 3 of the clinical trials conducted by GW Pharmaceuticals and the Ohio State University on the effectiveness of Epidiolex, results showed that the cannabis-based drug lowered the number of epileptic seizures experienced by children with Lennox-Gastaut syndrome by half. What Is Lennox-Gastaut Syndrome? The Lennox-Gastaut syndrome is one of the rare forms […]

by